IMATIB contains Imatinib mesylate which belongs to a group of medicines called corticosteroids which reduces inflammation. It is indicated to treat chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia in adults and children.
Medicince introduction including background, function, caution, etc.
Indication Chronic myeloid leukaemia Philadelphia chromosome positive acute lymphoblastic leukaemia Myelodysplastic/myeloproliferative diseases Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia Gastrointestinal stromal tumours Dermatofibrosarcoma protuberanss. Side Effects Edema, nausea, vomiting, muscle cramps Mechanism Of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia